The abstract is read at the publisher; the summary is JClub's.
In Botswana’s Tsepamo birth outcomes surveillance (Aug 15, 2014–Aug 15, 2022), neural tube defects occurred in 0·11% of 11 110 dolutegravir-at-conception exposures.
- Why it matters: A prior preliminary safety signal linked neural tube defects to dolutegravir exposure from conception, creating uncertainty that required complete, up-to-date surveillance through 2022.
- What they did: The study examined live infants and stillbirths in public hospitals, classified major abnormalities via medical geneticist review of photographs, and compared age-adjusted prevalence between dolutegravir and non-dolutegravir ART at conception.
- The result: Neural tube defect prevalence was similar for dolutegravir (0·11%, 95% CI 0·06–0·19) versus non-dolutegravir ART (0·10%, 0·07–0·15; age-adjusted difference -0·02%, 95% CI -0·09 to 0·05), with no detectable increase.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.